GNH USA

Europe — EMA

Nitisinone Dipharma

GNH USA supplies Nitisinone Dipharma (Nitisinone), a 4‑hydroxyphenylpyruvate dioxygenase inhibitor for hereditary tyrosinemia type I.

Nitisinone

Request sourcing

1
Pack/s

What is Nitisinone?

Nitisinone, the active ingredient in Nitisinone Dipharma, is a 4‑hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of hereditary tyrosinemia type I in affected patients, helping to prevent the buildup of toxic metabolic intermediates.

GNH USA supplies Nitisinone Dipharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

What is Nitisinone used for?

Nitisinone is used to manage disorders of tyrosine metabolism, specifically hereditary tyrosinemia type I.

- Hereditary tyrosinemia type I: reduces accumulation of toxic metabolites, improves liver function and supports metabolic control. - Alkaptonuria (off‑label): lowers homogentisic acid production, potentially slowing ochronotic pigment deposition. - Tyrosine‑related metabolic disorders (investigational): may modulate tyrosine catabolism under clinical study.

What are the side effects of Nitisinone?

Nitisinone may cause a range of adverse reactions, from mild to severe. Patients should be monitored regularly for any new symptoms.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional, may improve with food. - Vomiting: transient episodes. - Abdominal pain: mild discomfort. - Fatigue: generalized tiredness. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Liver failure: signs of jaundice or elevated enzymes. - Severe hypoglycemia: dizziness, confusion, loss of consciousness. - Neutropenia: increased infection risk. - Peripheral neuropathy: tingling or numbness. - Anaphylaxis: rapid onset of breathing difficulty, swelling, or hives.

What precautions apply to Nitisinone?

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for potential complications.

- Liver function monitoring: check transaminases and bilirubin regularly. - Plasma tyrosine levels: maintain within therapeutic range to avoid toxicity. - Renal impairment: adjust dosing and monitor creatinine. - Hypersensitivity: discontinue if allergic reactions occur. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

What does Nitisinone interact with?

Nitisinone can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other HPPD inhibitors: additive effect on tyrosine metabolism. - Strong CYP inducers (e.g., rifampin): may reduce nitisinone exposure. - Warfarin: increased anticoagulant effect, risk of bleeding.

Moderate Interactions (Monitor Closely): - Acetaminophen: potential hepatic stress, monitor liver enzymes. - Oral contraceptives: possible alteration of hormone levels. - Statins: increased risk of muscle toxicity, observe for myopathy.

Frequently asked questions

What is Nitisinone Dipharma used for?+
Nitisinone Dipharma contains nitisinone, an HPPD inhibitor indicated for the treatment of hereditary tyrosinemia type I. The drug works by blocking a key step in tyrosine breakdown, thereby preventing the accumulation of toxic metabolites that can damage the liver and kidneys.
How does nitisinone work in the body?+
Nitisinone selectively inhibits the enzyme 4‑hydroxyphenylpyruvate dioxygenase, which is essential for converting tyrosine into downstream metabolites. By blocking this enzyme, the drug stops the formation of harmful substances such as fumarylacetoacetate, reducing metabolic toxicity in patients with hereditary tyrosinemia type I.
What is the usual dose of Nitisinone Dipharma?+
The dosage of Nitisinone Dipharma is determined by the prescribing physician based on the patient’s age, weight, disease severity, and laboratory parameters. Healthcare professionals adjust the dose to achieve optimal metabolic control while minimizing adverse effects.
Is Nitisinone safe during pregnancy or breastfeeding?+
Safety data for nitisinone in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.
How do I order Nitisinone Dipharma from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.
How does Nitisinone compare with other treatments for hereditary tyrosinemia type I?+
Nitisinone is the primary disease‑modifying therapy for hereditary tyrosinemia type I, directly targeting the metabolic defect. Alternative approaches, such as liver transplantation, address end‑stage organ damage but do not correct the underlying enzymatic deficiency. Nitisinone therefore offers a less invasive, long‑term management option.
What are the recommended storage conditions for Nitisinone Dipharma?+
Nitisinone Dipharma should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.
How is Nitisinone Dipharma administered?+
The medication is taken orally, usually as a tablet or capsule, with water. It can be taken with or without food, but consistent administration with regard to meals helps maintain stable plasma concentrations. Patients should follow the prescribing clinician’s instructions for timing and dosing.
What are the most serious risks associated with Nitisinone Dipharma?+
Serious risks include liver failure, severe hypoglycemia, neutropenia, peripheral neuropathy, and rare anaphylactic reactions. Patients should be monitored regularly for liver enzymes, blood glucose, complete blood counts, and any neurological symptoms. Prompt medical attention is required if serious adverse events are suspected.
Who should not use Nitisinone Dipharma?+
Nitisinone is contraindicated in individuals with known hypersensitivity to nitisinone or any of its excipients. Caution is advised for patients with severe hepatic impairment, uncontrolled metabolic disorders, or those taking interacting medications that may exacerbate toxicity. The drug should only be used under specialist supervision.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Nitisinone
Route
Oral Use
Manufacturer
Dipharma Arzneimittel Gmbh
Origin
EU

Related products

Nitisinone 2 mg/1

Nitisinone 2 mg/1

Nitisinone · 2 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Nitisinone 5 mg/1

Nitisinone 5 mg/1

Nitisinone · 5 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Nitisinone 10 mg/1

Nitisinone 10 mg/1

Nitisinone · 10 mg

Nitisinone
CAPSULE
Endo USA, Inc.
USA
Mdk-Nitisinone 2 mg

Mdk-Nitisinone 2 mg

Nitisinone · 2 MG

Mdk-Nitisinone
CAPSULE
MENDELIKABS INC
CANADA